It’s time for our holiday break here at Endpoints News, and like a lot of you, we’ve been prepping for 2022. Anyone who’s spent some time in industry can tell you the past decade has shoved the drug…
A little over a week after French regulators decided against authorizing Merck’s Covid-19 antiviral pill, the country has canceled its order, according to multiple reports. A Merck spokesperson told…
Deck the halls with more appointments in the last Peer Review for 2021. Thanks for reading every week! → When the calendar flips to 2022, Joan Shen is out at I-Mab ‘to pursue other interests,’ leaving…
A low profile, Chinese biotech has been working on developing drugs for diabetes and metabolic disorders. Now, the company, known as Innogen Pharmaceutical Technology, has nabbed $120 million in…
A Danish bio industrial scale-up company has landed an $86 million investment from Novo Holdings, and it’s hoping to build on a technology base from Novozymes. And with that investment will come a new…
Expression Therapeutics’ new cell and viral vector manufacturing site is up and running in Cincinnati. The 43,000 square-foot site will provide end-to-end R&D capabilities and both early phase- and…
Even after agreeing to sell off $20 billion in shares back to Roche in November, Novartis got a bit more from its crosstown rival — successfully getting ahold of Roche’s head of neuro and rare disease…
Arrowhead Pharmaceuticals has purchased 13 acres of land in Wisconsin’s Verona Technology Park and will build a 140,000-square-foot drug manufacturing facility. The company will spend between $200…
The centerpiece of Novartis’s $9.7 billion buyout of the Medicines Company can finally go to market. Branded Leqvio, the small interfering RNA therapy long known as inclisiran is the first and only…
You may sense a theme in our Top 10 most read stories this year, and it’s not a surprise. Six out of 10 stories had something to do with COVID-19.
